Antibodies specific for CLL-1

Inventors

Jiang, Ping • KARSUNKY, Holger • Tressler, Rob

Assignees

Onk Therapeutics Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10723805-B2

Patent

Publication Date

2020-07-28

Expiration Date


Abstract

Provided herein are antibodies specific for CLL-1.

Core Innovation

The invention relates to targeting CLL-1, also described as CLEC12A/DCAL2/MICL, in acute myelogenous leukemia (AML) and other myeloproliferative disorders, and to using CLL-1-specific antibodies for treatment and detection or monitoring. The described antibodies bind CLL-1 with high affinity and are reported to bind high percentages of AML primary cells and human/cynomolgus CLL-1, with epitopes requiring stalk plus lectin, where lectin alone is insufficient.

A central aspect is that CLL-1 is not expressed on normal CD34+ hematopoietic stem cells (HSCs), while CLL-1 expression is associated with leukemic stem cells (LSCs). The content describes antibody-mediated functional activities including cytotoxicity through CDC and ADCC, and cytotoxic agent activity for antibody conjugates (ADC), with inhibition of AML cell growth and colony formation while sparing normal HSCs.

The content further describes in vivo activity in xenograft models, including NOD/SCID/NSG, with reduced tumor burden and effects on AML cancer stem cells. The antibodies are also described as enabling diagnostic and theranostic uses through labeled antibodies, including detection by FACS, to detect CLL-1+ cells and diagnose or monitor myeloproliferative disorders, and include competitive binding information and antibody clone, epitope set, and SEQ ID NO-based CDR definitions.

Claims Coverage

The independent claim covers treatment of a myeloproliferative disorder selected from AML, CML, CMML, and MDS by administering a pharmaceutical composition comprising a specifically defined antibody. The claim specifies three inventive features relating to the antibody type, its cargo or effector function, and the defined heavy-chain and light-chain CDR sets.

Treatment of a selected myeloproliferative disorder with a CDR-defined antibody pharmaceutical composition

A method of treating a myeloproliferative disorder in an individual, where the myeloproliferative disorder is selected from acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), and myelodisplastic syndrome (MDS), by administering a pharmaceutical composition comprising an antibody selected for defined heavy-chain and light-chain CDR sets based on SEQ ID NOs.

Antibody conjugated to a cytotoxic or therapeutic compound, or capable of ADCC or CDC

The pharmaceutical composition includes an antibody that is conjugated to a cytotoxic or therapeutic compound or has the ability to induce antibody dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) activity, thereby treating the myeloproliferative disorder in the individual.

Heavy-chain and light-chain CDR SEQ ID NO sets defining multiple antibody embodiments

The antibody is selected from embodiments comprising heavy chain CDRs of SEQ ID NOs:51, 59, and 67 with light chain CDRs of SEQ ID NOs:75, 83, and 91; or heavy chain CDRs of SEQ ID NOs:52, 60, and 68 with light chain CDRs of SEQ ID NOs:76, 84, and 92; or heavy chain CDRs of SEQ ID NOs:53, 61, and 69 with light chain CDRs of SEQ ID NOs:77, 85, and 93.

Overall, the claim coverage centers on treating AML, CML, CMML, or MDS by administering a pharmaceutical composition containing a CLL-1-targeting antibody defined by specific SEQ ID NO-based heavy-chain and light-chain CDR sets, where the antibody is either conjugated to a cytotoxic or therapeutic compound or is capable of inducing ADCC and/or CDC.

Stated Advantages

Inhibit AML cell growth and colony formation while sparing normal HSCs.

Reduce tumor burden in xenograft models.

Provide effects on AML cancer stem cells.

Enable detection of CLL-1+ cells and diagnosis or monitoring of myeloproliferative disorders using labeled antibodies, including FACS.

Documented Applications

Treatment of myeloproliferative disorders selected from acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), and myelodisplastic syndrome (MDS) by administering a pharmaceutical composition comprising an antibody conjugated to a cytotoxic or therapeutic compound or capable of inducing ADCC or CDC activity.

Diagnostic or theranostic detection by labeled antibodies, including FACS, to detect CLL-1+ cells and diagnose or monitor myeloproliferative disorders.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.